615 related articles for article (PubMed ID: 33165872)
1. TRPV1-Targeted Drugs in Development for Human Pain Conditions.
Iftinca M; Defaye M; Altier C
Drugs; 2021 Jan; 81(1):7-27. PubMed ID: 33165872
[TBL] [Abstract][Full Text] [Related]
2. TRPV1 signaling: mechanistic understanding and therapeutic potential.
Xia R; Samad TA; Btesh J; Jiang LH; Kays I; Stjernborg L; Dekker N
Curr Top Med Chem; 2011; 11(17):2180-91. PubMed ID: 21671876
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.
Wong GY; Gavva NR
Brain Res Rev; 2009 Apr; 60(1):267-77. PubMed ID: 19150372
[TBL] [Abstract][Full Text] [Related]
4. Multisteric TRPV1 nocisensor: a target for analgesics.
Szolcsányi J; Sándor Z
Trends Pharmacol Sci; 2012 Dec; 33(12):646-55. PubMed ID: 23068431
[TBL] [Abstract][Full Text] [Related]
5. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
[TBL] [Abstract][Full Text] [Related]
6. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists.
Cui M; Honore P; Zhong C; Gauvin D; Mikusa J; Hernandez G; Chandran P; Gomtsyan A; Brown B; Bayburt EK; Marsh K; Bianchi B; McDonald H; Niforatos W; Neelands TR; Moreland RB; Decker MW; Lee CH; Sullivan JP; Faltynek CR
J Neurosci; 2006 Sep; 26(37):9385-93. PubMed ID: 16971522
[TBL] [Abstract][Full Text] [Related]
7. Targeting TRPV1 for pain relief: limits, losers and laurels.
Szallasi A; Sheta M
Expert Opin Investig Drugs; 2012 Sep; 21(9):1351-69. PubMed ID: 22780443
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of TRPV channel block on polymodal activation of rat cutaneous nociceptors in vitro.
St Pierre M; Reeh PW; Zimmermann K
Exp Brain Res; 2009 Jun; 196(1):31-44. PubMed ID: 19404626
[TBL] [Abstract][Full Text] [Related]
9. Novel piperazine urea derivatives as highly potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
Hu J; Gao M; Zhang Y; Wang Y; Qiao Z; Zhang W; Wang Q; Yan L; Qian H
Bioorg Chem; 2021 Oct; 115():105229. PubMed ID: 34364049
[TBL] [Abstract][Full Text] [Related]
10. Capsaicin and sensory neurones: a historical perspective.
Szolcsányi J
Prog Drug Res; 2014; 68():1-37. PubMed ID: 24941663
[TBL] [Abstract][Full Text] [Related]
11. Transient receptor potential vanilloid 1 as a therapeutic target in analgesia.
Szolcsányi J; Pintér E
Expert Opin Ther Targets; 2013 Jun; 17(6):641-57. PubMed ID: 23421411
[TBL] [Abstract][Full Text] [Related]
12. A patent review of transient receptor potential vanilloid type 1 modulators (2014-present).
Gao M; Wang Y; Liu L; Qiao Z; Yan L
Expert Opin Ther Pat; 2021 Feb; 31(2):169-187. PubMed ID: 33377418
[No Abstract] [Full Text] [Related]
13. 7-tert-Butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, a classic polymodal inhibitor of transient receptor potential vanilloid type 1 with a reduced liability for hyperthermia, is analgesic and ameliorates visceral hypersensitivity.
Nash MS; McIntyre P; Groarke A; Lilley E; Culshaw A; Hallett A; Panesar M; Fox A; Bevan S
J Pharmacol Exp Ther; 2012 Aug; 342(2):389-98. PubMed ID: 22566669
[TBL] [Abstract][Full Text] [Related]
14. TRPV1 receptors in sensitisation of cough and pain reflexes.
Adcock JJ
Pulm Pharmacol Ther; 2009 Apr; 22(2):65-70. PubMed ID: 19141328
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature.
Reilly RM; McDonald HA; Puttfarcken PS; Joshi SK; Lewis L; Pai M; Franklin PH; Segreti JA; Neelands TR; Han P; Chen J; Mantyh PW; Ghilardi JR; Turner TM; Voight EA; Daanen JF; Schmidt RG; Gomtsyan A; Kort ME; Faltynek CR; Kym PR
J Pharmacol Exp Ther; 2012 Aug; 342(2):416-28. PubMed ID: 22570364
[TBL] [Abstract][Full Text] [Related]
16. Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).
Lee Y; Hong S; Cui M; Sharma PK; Lee J; Choi S
Expert Opin Ther Pat; 2015 Mar; 25(3):291-318. PubMed ID: 25666693
[TBL] [Abstract][Full Text] [Related]
17. N-palmitoyl-vanillamide (palvanil) is a non-pungent analogue of capsaicin with stronger desensitizing capability against the TRPV1 receptor and anti-hyperalgesic activity.
De Petrocellis L; Guida F; Moriello AS; De Chiaro M; Piscitelli F; de Novellis V; Maione S; Di Marzo V
Pharmacol Res; 2011 Apr; 63(4):294-9. PubMed ID: 21215315
[TBL] [Abstract][Full Text] [Related]
18. Modulation of TRPV1 channel function by natural products in the treatment of pain.
Abbas MA
Chem Biol Interact; 2020 Oct; 330():109178. PubMed ID: 32738201
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the TRPV1 channel: current clinical trials and recent patents with focus on neurological conditions.
De Petrocellis L; Moriello AS
Recent Pat CNS Drug Discov; 2013 Dec; 8(3):180-204. PubMed ID: 24330123
[TBL] [Abstract][Full Text] [Related]
20. TRPV1 antagonists as a potential treatment for hyperalgesia.
Roberts LA; Connor M
Recent Pat CNS Drug Discov; 2006 Jan; 1(1):65-76. PubMed ID: 18221192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
